Open original FDA record ↗Recall record
- FDA identifier
- Z-2615-2023
- Company in FDA record
- Abbott Medical
- FDA classification date
- Sep 19, 2023
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Due to Bluetooth malfunction on a subset of Implantable Cardioverter Defibrillator (ICD) and Cardia Resynchronization Therapy Defibrillator *CRT-D) devices that were manufactured prior to April 2022 as a result of crystal component issue within the Bluetooth Low Energy (BLE) circuit. This results in the device entering an inductive telemetry only mode with loss of Bluetooth communication. In some instances, thought BLE communication is unavailable, the circuit may remain in a state which draws excessive power affecting battery longevity.
Source facts
- Action
- On 08/16/2023, the firm sent to U.S. customers an "URGENT MEDICAL DEVICE CORRECTION" Letter (via mail, email or hand-delivery) informing physicians and healthcare professionals that there is a potential for a Bluetooth (BLE) circuit component issue on a subset of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy Defibrillators manufactured prior to April 2022. The issue is associated with a risk of loss of Bluetooth communication (and therefore a loss of remote monitoring), higher-than-normal current consumption, and reduced device battery longevity. Patient Management Recommendations: 1. Prophylactic device replacement is not recommended as new firmware version pr00.10.87.04 eliminates the potential for loss of therapy between follow-up due to unrecognized decreased device longevity. 2. Determine the firmware version of devices followed at clinics by reviewing the instructions in Appendix A and the device list in Appendix B. 3. Patients with firmware version pr00.10.87.00 or firmware version undetermined, upgrade devices to firmware version pr00.10.87.04: -Prioritize in-clinic firmware upgrade for the specific devices from the 1,500 device sub-group (listed in Appendix B) -For remaining patients, schedule the next follow-up in clinic to complete firmware upgrade. 3. Following firmware upgrade, continue to follow patients routinely 4. If device experience a loss of Bluetooth communication, contact Abbott Technical Support at 1-800-722-3774 (U.S.). In addition, a list of Abbott advisories is available at https://www.cardiovascular.abbott/us/en/hcp/product-advisories.html Abbott has also include a web version of the Customer Notification Letter at https://www.cardiovascular.abbott/content/dam/cv/cardiovascular/pdf/reports/US-Abbott-Communication-BLE-Communication-Final-FDA-v2.pdf
- Initiated
- 2023-08-16
- Root cause
- Component design/selection
- Distribution
- U.S.: Nation-wide O.U.S.: Australia, Austria, Bahrain, Belgium, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Italy, Korea, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Malaysia, Nepal, Netherlands, New Zealand, Norway, Oman, Poland, Portugal, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Thailand, United Arab Emirates, United Kingdom. Latin America - Pending
- Recall number
- Z-2615-2023
- Recall status
- Open, Classified
- CDRH record ID
- 202931
- FDA classified
- 2023-09-19
- Recall event number
- 92923